EPH Receptor A4 Antikörper (C-Term)
Kurzübersicht für EPH Receptor A4 Antikörper (C-Term) (ABIN2469317)
Target
Alle EPH Receptor A4 (EPHA4) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- C-Term
-
Spezifität
- BLAST analysis of the peptide immunogen showed no homology with other human proteins.
-
Aufreinigung
- Immunoaffinity Chromatography
-
Immunogen
- EPHA4 antibody was raised against a peptide located in the C-Terminal domain of EPHA4 (Human).
-
-
-
-
Applikationshinweise
- EPHA4 antibody can be used in immunohistochemistry starting at 7.3 μg/mL.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- PBS, 0.1 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- As with all antibodies avoid freeze/thaw cycles.
-
Lagerung
- 4 °C/-80 °C
-
Informationen zur Lagerung
- EPHA4 antibody should be stored long term (months) at -80 °C and short term (days) at 4 °C.
-
-
- EPH Receptor A4 (EPHA4)
-
Andere Bezeichnung
- EPHA4
-
Hintergrund
- Nak1, a NR4 Nerve Growth Factor-Like receptor, has been shown to affect the hypothalamic-pituitary axis, neuronal differentiation, neuroendocrine regulation of adrenocortical function, and T-cell apoptosis. Nak1 also is known as nuclear receptor Tr3 and is similar to mouse Nur77 and rat NGFI-B. It is encoded by one of the immediate early genes (IEG) in response to nerve growth factor and other serum growth factors. Nak1 can bind to DNA as a monomer, homodimer, or heterodimer (with retinoid X receptors). Nak1 has been shown to inhibit vascular lesion formation and could serve as a novel target in the treatment of vascular diseases.
-
Gen-ID
- 2043
-
UniProt
- P54764
-
Pathways
- RTK Signalweg
Target
-